KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amgen (AMGN) Tax Provisions (2016 - 2026)

Amgen has reported Tax Provisions over the past 18 years, most recently at $265.0 million for Q1 2026.

  • For Q1 2026, Tax Provisions rose 9.05% year-over-year to $265.0 million; the TTM value through Mar 2026 reached $1.3 billion, up 79.5%, while the annual FY2025 figure was $1.3 billion, 143.74% up from the prior year.
  • Tax Provisions for Q1 2026 was $265.0 million at Amgen, up from $181.0 million in the prior quarter.
  • Over five years, Tax Provisions peaked at $705.0 million in Q3 2025 and troughed at $45.0 million in Q1 2024.
  • A 5-year average of $234.2 million and a median of $214.0 million in 2022 define the central range for Tax Provisions.
  • Biggest five-year swings in Tax Provisions: tumbled 92.51% in 2024 and later skyrocketed 440.0% in 2025.
  • Year by year, Tax Provisions stood at $132.0 million in 2022, then tumbled by 35.61% to $85.0 million in 2023, then surged by 82.35% to $155.0 million in 2024, then rose by 16.77% to $181.0 million in 2025, then skyrocketed by 46.41% to $265.0 million in 2026.
  • Business Quant data shows Tax Provisions for AMGN at $265.0 million in Q1 2026, $181.0 million in Q4 2025, and $705.0 million in Q3 2025.